Physician profile
John Hardin
NPI 1417969551
$1,959.31
in general payments reported to CMS, 2019-2025
18 companies · $454 in 2025
The $454 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $45.77 · 2021: $352 · 2022: $281 · 2023: $558 · 2024: $82.16 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702 · Travel and Lodging: $196 · Education: $196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.34 |
| Travel and Lodging | $196.17 |
| Education | $196.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $452.77 | 2021-2025 | Libtayo |
| Janssen Biotech, INC. | $359.05 | 2019-2025 | Tremfya |
| Musculoskeletal Transplant Foundation INC. | $221.62 | 2023-2025 | |
| Abbvie INC. | $179.81 | 2021-2023 | |
| Sun Pharmaceutical Industries INC. | $169.58 | 2021-2024 | Ilumya |
| Galderma Laboratories, L.P. | $128.75 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $99.96 | 2021-2025 | |
| Amgen INC. | $88.11 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $52.20 | 2022-2023 | |
| Incyte Corporation | $43.35 | 2025 | Opzelura |
| Dermira, INC. | $39.36 | 2019-2020 | |
| Celgene Corporation | $37.21 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $26.67 | 2024 | Sotyktu |
| Ucb, INC. | $15.26 | 2022 | |
| Lilly USA, LLC | $13.46 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
| Genzyme Corporation | $12.46 | 2022 | |
| Organon LLC | $6.52 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hardin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.